| P/E (FY) | 33.2 | Sales (TTM) | JPY 947.75B |
| Earnings (TTM) | JPY 253.09B | ROE | 25.38% |
| Net Margin | 26.70% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 16.58% | Sales Growth 3Y | 9.41% |
HOYA, a med-tech company, provides high-tech and medical products in Japan, Asia, the Americas, Europe and internationally through its Life Care and Information and Communications segments. Life Care offerings include eyeglasses, contact lenses, medical endoscopes, intraocular lenses, surgical instruments and orthopedic and dental implants, plus the Eyecity contact-lens retail chain. Information and Communications products include mask blanks and photomasks, hard-disk glass disks, and optical glass and lenses.
| Market Cap | $51.05B | Trading Days | 4017 |
| 52W High | 30400.00 |
| 52W Low | 17500.00 |
| % Off High | −18.67% |
| YTD | 4.39% | 1Y | 29.28% |
| 3Y | 55.55% | 5Y | 66.37% |
| 10Y | 611.08% | Since incept. (ann.) | 16.58% |
| Ann. Volatility (1Y) | 32.63% | Ann. Volatility (3Y) | 34.74% |
| Sharpe (1Y) | 1.03 | Sharpe (3Y) | 0.65 |
| Max Drawdown (1Y) | −20.38% | Max Drawdown (3Y) | −33.03% |
| Beta (3Y, vs SPY) | 0.82 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| 207940.KS | Samsung Biologics Ltd | $48.95B | 101.5 |
| EW | Edwards Lifesciences Corp | $48.18B | 45.7 |
| ARGX.BR | argenx SE | $55.03B | — |
| BDX | BECTON DICKINSON & CO | $45.83B | 28.6 |
| IDXX | IDEXX LABORATORIES INC /DE | $44.93B | 43.5 |
| AGL | agilon health, inc. | $41.04B | — |
| IQV | IQVIA HOLDINGS INC. | $40.55B | 31.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| A | AGILENT TECHNOLOGIES, INC. | $39.69B | 30.8 |
| RVMD | Revolution Medicines, Inc. | $39.09B | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| BSX | BOSTON SCIENTIFIC CORP |
| $68.46B |
| 23.7 |
